Celgene reports detailed PFS data for Pomalyst triple combo in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III OPTIMISMM trial in 559 patients with relapsed or refractory multiple myeloma (MM) who

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE